IPP Bureau

Aragen launches ChemiSHE, India’s first women-led chemistry synthesis lab
Aragen launches ChemiSHE, India’s first women-led chemistry synthesis lab

By IPP Bureau - April 14, 2026

CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years

Alexion to showcase broad neurology pipeline at AAN 2026 with 20 presentations
Alexion to showcase broad neurology pipeline at AAN 2026 with 20 presentations

By IPP Bureau - April 14, 2026

The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies

New guidance aims to speed up diagnosis of childhood abdominal cancers
New guidance aims to speed up diagnosis of childhood abdominal cancers

By IPP Bureau - April 14, 2026

Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours

AKM and Kyoto University break ground with 2 µm PCSEL laser
AKM and Kyoto University break ground with 2 µm PCSEL laser

By IPP Bureau - April 14, 2026

Paves the way for next-gen ultra-precise gas sensing

Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development
Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development

By IPP Bureau - April 14, 2026

A major push to sharpen the future of cancer treatment is underway

Kolkata gets advanced liver care hub as Manipal Hospitals targets critical treatment gap
Kolkata gets advanced liver care hub as Manipal Hospitals targets critical treatment gap

By IPP Bureau - April 14, 2026

The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network

WHO unites 800+ institutions in historic global health push to prepare for next pandemic threat
WHO unites 800+ institutions in historic global health push to prepare for next pandemic threat

By IPP Bureau - April 14, 2026

Scientists at the forum warned of an increasingly volatile health landscape

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial
Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

By IPP Bureau - April 14, 2026

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

Thermo Fisher and Singapore’s PRECISE launch major proteomics push in 100,000-person study
Thermo Fisher and Singapore’s PRECISE launch major proteomics push in 100,000-person study

By IPP Bureau - April 14, 2026

The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen
GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

By IPP Bureau - April 14, 2026

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access

Kauvery Hospital conducts 4th edition of ECG Masterclass 2026; 400+ medical professionals attend
Kauvery Hospital conducts 4th edition of ECG Masterclass 2026; 400+ medical professionals attend

By IPP Bureau - April 14, 2026

Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”

India Pharma 2026 showcases sectoral transformation through four key plenary discussions
India Pharma 2026 showcases sectoral transformation through four key plenary discussions

By IPP Bureau - April 14, 2026

Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals

Briefs: Indoco Remedies and Panacea Biotec
Briefs: Indoco Remedies and Panacea Biotec

By IPP Bureau - April 14, 2026

Panacea Biotec receives LoA from CMSS

FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review
FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

By IPP Bureau - April 14, 2026

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial
Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

By IPP Bureau - April 14, 2026

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors

Latest Stories

Interviews

Packaging